Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
Public ClinicalTrials.gov record NCT04387461. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Study identification
- NCT ID
- NCT04387461
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- CG Oncology, Inc.
- Industry
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Interventions
- CG0070 Biological
- Pembrolizumab Injection Biological
- n-dodecyl-B-D-maltoside Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 7, 2020
- Primary completion
- Mar 6, 2023
- Completion
- May 27, 2024
- Last update posted
- Sep 24, 2024
2020 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California - San Diego | La Jolla | California | 92093 | — |
| University of California - Irvine | Orange | California | 92868 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Northwestern University | Tampa | Florida | 33612 | — |
| Johns Hopkins Medical Institution | Baltimore | Maryland | 21287 | — |
| Chesapeake Urology | Hanover | Maryland | 21076 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55902-9823 | — |
| New York University | New York | New York | 10003 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Keystone Urology Specialists | Lancaster | Pennsylvania | 17604 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Spokane Urology | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04387461, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2024 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04387461 live on ClinicalTrials.gov.